That aberrant p16 expression was not only seen in endothelial cells of a few cancers, but also in rare instances in endothelial cells in non-neoplastic tissue and in fibroblasts of the tumor stroma demonstrates, that substantial p16 upregulation can occasionally also occur in non-neoplastic tissue proliferation. Here, CDKN2A is linked to cancer.